LINZAGOLIX MAY ADDRESS THE LONG-TERM TREATMENT NEEDS OF WOMEN WITH UTERINE FIBROIDS (UF) WHO HAVE CONTRAINDICATIONS TO HORMONAL ADD-BACK THERAPY (ABT): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS.

被引：0
|
作者：
Bradley, Linda D. [1 ]
Marsh, Erica E. [2 ]
Garner, Elizabeth [3 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] ObsEva Inc, Boston, MA USA
来源：
FERTILITY AND STERILITY | 2020年 / 114卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-931
引用
收藏
页码：E522 / E522
页数：1
相关论文
共 4 条
  • [1] Linzagolix With and Without Hormonal Add-Back Therapy for the Treatment of Symptomatic Uterine Fibroids: Two Randomized, Placebo-Controlled, Phase 3 Trials
    Donnez, Jacques
    Taylor, Hugh S. S.
    Stewart, Elizabeth A. A.
    Bradley, Linda
    Marsh, Erica
    Archer, David
    Al-Hendy, Ayman
    Petraglia, Felice
    Watts, Nelson
    Gotteland, Jean-Pierre
    Bestel, Elke
    Terrill, Paul
    Loumaye, Ernest
    Humberstone, Andrew
    Garner, Elizabeth
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2022, 77 (12) : 741 - 742
  • [2] Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials
    Donnez, Jacques
    Taylor, Hugh S.
    Stewart, Elizabeth A.
    Bradley, Linda
    Marsh, Erica
    Archer, David
    Al-Hendy, Ayman
    Petraglia, Felice
    Watts, Nelson
    Gotteland, Jean-Pierre
    Bestel, Elke
    Terrill, Paul
    Loumaye, Ernest
    Humberstone, Andrew
    Garner, Elizabeth
    LANCET, 2022, 400 (10356): : 896 - 907
  • [3] EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS.
    Stewart, Elizabeth A.
    Taylor, Hugh S.
    Taylor, Robert N.
    Donnez, Jacques
    Bestel, Elke
    Gotteland, Jean-Pierre
    Humberstone, Andrew
    Garner, Elizabeth
    FERTILITY AND STERILITY, 2020, 114 (03) : E522 - E522
  • [4] Long term secondary efficacy of linzagolix for heavy menstrual bleeding (HMB) due to uterine fibroids (UF): 52-week results from two placebo-controlled, randomized, phase 3 trials
    Taylor, H.
    Donnez, J.
    Petraglia, F.
    Danielsson, K. Gemzell
    Renner, S.
    Bestel, E.
    Gotteland, J. P.
    Humberstone, A.
    Garner, E.
    HUMAN REPRODUCTION, 2021, 36 : 59 - 59
1